Extracorporeal Rheopheresis in the Treatment of Acute Ischemic Stroke
- 1 April 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Stroke
- Vol. 30 (4) , 787-792
Abstract
Background and Purpose —Extracorporeal rheopheresis is a safe method to optimize hemorheology. Our aim was to determine whether treatment with extracorporeal rheopheresis in patients with acute ischemic hemispheric stroke improves cerebral perfusion as assessed with serial 99m Tc–ethyl-cysteinate-dimer single-photon emission CT ( 99m Tc-ECD SPECT). We also investigated how clinical outcome is associated with treatment and imaging results. Methods —Thirty-three patients (mean age, 64±10 years) with acute ischemic hemispheric stroke were included in a prospective, randomized, parallel group pilot study. First treatment with or without extracorporeal rheopheresis took place within 12 hours after the onset of symptoms and was repeated 3 times at intervals of 24 hours. Hemorheological parameters were measured before and after each session. Each patient underwent 99m Tc-ECD SPECT immediately before treatment, 6 to 8 hours after treatment, and after 5 days. A semiquantitative SPECT graded scale was used to measure depth and extent of activity deficits and thus to quantify the perfusion deficit. Results —Seventeen patients were actively treated with extracorporeal rheopheresis, and 16 patients did not receive extracorporeal rheopheresis. After 3 months, no differences were found in the functional or neurological outcome. Despite a rapid, sustained decrease of plasma viscosity and erythrocyte aggregation in the rheopheresis group, there was no significant difference in the SPECT graded scale after therapy between the 2 groups. Patients with early reperfusion (decrease in the SPECT graded scale >25% 6 to 8 hours after therapy compared with the baseline examination) experienced a better functional outcome (Modified Rankin Scale) after 3 months compared with patients without reperfusion ( P =0.04). Conclusions —Since quantitative flow mapping and clinical follow-up did not reveal any differences between patients who were treated with extracorporeal rheopheresis and controls, it appears very unlikely that extracorporeal rheopheresis enhances reperfusion after acute cerebral ischemia.Keywords
This publication has 19 references indexed in Scilit:
- Differentiation between Transient Ischemic Attack and Ischemic Stroke within the First Six Hours after Onset of Symptoms by Using 99mTc-ECD-SPECTJournal of Cerebral Blood Flow & Metabolism, 1998
- Multinational Randomised Controlled Trial of Lubeluzole in Acute Ischaemic StrokeCerebrovascular Diseases, 1998
- Thrombolytic Therapy with Streptokinase in Acute Ischemic StrokeNew England Journal of Medicine, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- The therapeutic window in ischemic brain injuryCurrent Opinion in Neurology, 1995
- Viability thresholds and the penumbra of focal ischemiaAnnals of Neurology, 1994
- The ischemic penumbra, injury thresholds, and the therapeutic window for acute strokeAnnals of Neurology, 1994
- Thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: evaluation with rCBF-SPECTActa Neurologica Scandinavica, 1991
- Thresholds of focal cerebral ischemia in awake monkeysJournal of Neurosurgery, 1981
- Effects of lipoproteins on plasma viscosityAtherosclerosis, 1981